Biospecimen Collection (NCT06263153)

Name: Biospecimen Collection trial for Bladder Urothelial Carcinoma (NCT06263153)
Uploaded: 2026-10-31T21:28:52.765Z
Duration: 1 min 30 s
Description: Biospecimen Collection trial for Bladder Urothelial Carcinoma (NCT06263153). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06263153.

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy: a one-minute explainerNCT062631531 min

Biospecimen Collection trial for Bladder Urothelial Carcinoma (NCT06263153). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with node-negative, nonmetastatic muscle-invasive bladder cancer showing high FGFR1, FGFR2 or FGFR3 expression. They must refuse or be unsuitable for cisplatin chemotherapy, yet be fit for planned bladder-removal surgery.

The idea: give daily futibatinib tablets and durvalumab infusions every four weeks for up to three cycles before surgery. Futibatinib blocks FGFR growth signaling; durvalumab blocks PD-L1 immune suppression. Researchers examine the removed tissue for remaining cancer and monitor safety.

This phase 2 study plans 24 patients. Yuanquan Yang leads recruiting sites in Columbus and Cleveland.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.